Denosumab (Prolia): Why Stopping It Is Different From Every Other Bone Drug

What denosumab is

Denosumab, sold as Prolia for osteoporosis, is an injection given under the skin every six months. It is a monoclonal antibody that blocks RANK ligand, a signalling protein the body uses to tell bone-resorbing cells to get to work. Block that signal and bone breakdown slows sharply.

It builds bone density steadily and, unlike oral bisphosphonates, does not depend on you taking a tablet correctly on an empty stomach and staying upright. For many women it is the more effective and more tolerable option.

The part that is often not explained

Denosumab does not deposit in bone. Bisphosphonates bind to the mineral surface and keep working for months or years after the last dose. Denosumab clears from the body, and when it does, the suppressed bone-resorbing cells come back — not to baseline, but overshooting it.

This is the rebound phenomenon. Bone turnover markers rise sharply, the density gained during treatment is lost quickly, and spontaneous vertebral fractures — often several at once, in women who never had a fracture before — have been reported. The loss typically happens within 6 to 12 months of a missed or stopped dose. Published estimates of the proportion of women who sustain multiple vertebral fractures after stopping without follow-on treatment range widely across studies, roughly in the 10% region and higher in some series.

Two consequences follow, and they are the most practical things on this page:

• A late injection is not a minor scheduling problem. The six-month interval is not a suggestion. If you are going to be travelling, changing insurance, or between prescribers, arrange the next dose before the gap, not after it.
• Stopping is a planned medical transition, not simply not renewing. Denosumab is the one osteoporosis drug you should never quietly stop.

How stopping is managed

The standard approach is antiresorptive bridging: moving to a bisphosphonate to hold the gains. The European Calcified Tissue Society published guidance on this in 2021, and it is the framework most clinicians work from.

Two honest caveats from the literature. Bisphosphonate bridging attenuates but does not fully prevent the bone loss — it reduces the problem rather than eliminating it. And raloxifene has specifically been shown not to control the high turnover or the spontaneous vertebral fracture risk after denosumab, so it is not an adequate substitute in this situation. Individual cases of vertebral fracture despite oral risedronate bridging have also been published.

Timing matters too: in higher-risk patients, switching too early — while density is still low — has been described as increasing rather than reducing rebound fracture risk. This is a decision for a clinician who treats osteoporosis regularly, not a general recommendation that can be read off a webpage.

Who denosumab suits

• Postmenopausal women at high fracture risk, particularly where oral bisphosphonates are not tolerated or not absorbed
• Reduced kidney function, where bisphosphonates are often unsuitable
• Situations where twice-yearly dosing improves the odds of the treatment actually being taken

Before and during treatment

• Dental work first. Osteonecrosis of the jaw is rare but is associated with invasive dental procedures during antiresorptive treatment. Get planned extractions and implants done before starting where possible.
• Calcium and vitamin D must be adequate. Denosumab can cause hypocalcaemia, and the risk is higher with low vitamin D or impaired kidney function.
• Know your next injection date. Put it in a calendar with a reminder a month ahead.

Questions worth asking

• "How long do you expect me to stay on this, and what is the exit plan?"
• "If I stop, what bridging treatment do you use and when does it start relative to my last injection?"
• "What happens if a dose is delayed — how much delay is acceptable?"
• "Do I need dental work done before we start?"

Denosumab compared with a bisphosphonate

What the appointment involves

The injection is given under the skin of the upper arm, thigh or abdomen and takes moments. There is no infusion time and no need to stay upright afterwards. Most women arrange it at the same visit as a blood test for calcium and kidney function.

Who should not have it, or needs care

• Low blood calcium must be corrected before starting — denosumab can lower it further.
• Significant kidney impairment raises the risk of hypocalcaemia even though the drug itself is usable at lower kidney function than bisphosphonates.
• Pregnancy — it is not used in women who may become pregnant.
• Planned invasive dental work is better completed first.

Rare effects worth knowing by name

Osteonecrosis of the jaw and atypical femoral fracture are both rare and both associated with the antiresorptive class rather than this drug uniquely. The practical signals are persistent jaw pain or a non-healing socket after dental work, and new thigh or groin pain that builds over weeks. Neither is a reason to avoid treatment when fracture risk is high, but both are reasons to report the symptom rather than wait for the next review.

What good follow-up looks like

• Bone density repeated at an interval your prescriber sets, not left open-ended
• Calcium and kidney function checked around injections
• A written date for the next injection, with a reminder a month ahead
• An explicit answer, in your notes, to the question of what happens when treatment ends